Monoclonal Antibodies as Therapeutic Agents

  • Manzoor M. KhanEmail author


In 1895, Hericourt and Richet reported the first clinical trials testing the principle of antibody production. They injected cancer cells into animals to obtain antiserum to treat cancer patients; this was the first time several patients with cancer were administered tailor-made serum for treatment. Several patients showed improvement, which was encouraging, but none of the patients were completely cured. These trials were repeated in the early 1900s but the results were not consistent. The problems included the variability of the antisera and the side effects of polyclonal antibodies – some of which were directed against self.

Paul Ehrlich, at the beginning of the twentieth century, first proposed the concept of “magic bullets.” He reasoned that the development of compounds that selectively target a disease-causing organism could potentially deliver toxins to that organism. The specificity of antibodies, which are extremely specific and bind to and attack one particular...


Acute Myeloid Leukemia Myeloma Cell Chimeric Monoclonal Antibody Chimeric Antibody Murine Antibody 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Albanell J, Codony J, Rovira A, Mellado B, et al. 2003. Mechanism of action of anti-HER2 monoclonal antibodies: Scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 532:253–268.PubMedGoogle Scholar
  2. Baca M, Presta LG, O’Connor SJ, Wells JA. 1997. Antibody humanization using monovalent phage display. J Biol Chem. 272:10678–10684.PubMedGoogle Scholar
  3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, et al. 2007. Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 66:921–926.PubMedGoogle Scholar
  4. Bennett JM, Kaminski MS, Leonard JP, Vase JM, et al. 2005. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and Iodine I 131 tositumomab. Blood. 1052: 4576–4582.Google Scholar
  5. Bielekova B, Richert N, Howard T, Blevins G, et al. 2004. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci. 101:8705–8708.Google Scholar
  6. Binder M, Otto F, Mertelsmann R, Veelken H, et al. 2006. The epitope recognized by rituximab. Blood. 108:1975–1978.PubMedGoogle Scholar
  7. Bonner JA, Harari PM, Giralt J, Azarmia N, et al. 2006. Radiotherapy plus centuximab for squamous-cell carcinoma of the head and neck. NEJM. 354:567–578.PubMedGoogle Scholar
  8. Bordigoni P, Dimicoli S, Clement L, Baumann C. 2006. Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. Br J Hematol. 135:382–385.Google Scholar
  9. Borro JM, De-la-Torre M, Miguelez C, Fernandez R, et al. 2005. Comparative study of basiliximab treatment in lung transplantation. Transplant Proc. 37:3996–3998.Google Scholar
  10. Boulianne GL, Hozumi N, Shulman MJ. 1984. Production of functional chimeric mouse/human antibody. Nature. 312:643–646.PubMedGoogle Scholar
  11. Boyne J, Elter T, Engert A. 2003. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. 14:520–535.Google Scholar
  12. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, et al. 2005. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 78:275–280.PubMedGoogle Scholar
  13. Brennan DC, Daller JA, Lake KD, Cibrik D. 2006. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. NEJM. 355:1967–1977.PubMedGoogle Scholar
  14. Bruggemann M, Witner G, Waldmann H, Neuberger MS. 1989. The immunogenicity of chimeric antibodies. J Exp Med. 170:2153–2157.PubMedGoogle Scholar
  15. Burton C, Kaczmarski R, Jan-Mohamed R. 2003. Interstitial pneumonitis related to rituximab therapy. NEJM. 348:2690–2691.PubMedGoogle Scholar
  16. Carter P, Presta L, Gorman CM, Ridgway JB, et al. 1992. Humanization of anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 89:4285–4289.Google Scholar
  17. Carter PJ. 2006. Potent antibody therapeutics by design. Nat Rev Immunol. 6:343–357.PubMedGoogle Scholar
  18. Cartron G, Watier H, Golay J, Solal-Celigny P. 2004. From bench to the bedside: Ways to improve rituximab efficacy. Blood. 104:2635–2642.PubMedGoogle Scholar
  19. Chothia C, Lesk AM, Tramontano A, Levitt M, et al. 1989. Conformations of immunoglobulin hypervariable regions. Nature. 342:877–883.PubMedGoogle Scholar
  20. Choy EH, Pnaayi GS. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. NEJM. 344:907–916.PubMedGoogle Scholar
  21. Clark M. 2000. Antibody humanization: A case of the “emperor’s new clothes?” Immunol. Today. 21:397–402.Google Scholar
  22. Coiffier B, Lepage E, Briere J, Herbrecht R, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. NEJM. 346:235–242.PubMedGoogle Scholar
  23. Connors JM. 2005. Radioimmunotherapy – hot new treatment for lymphoma. NEJM. 352: 496–498.PubMedGoogle Scholar
  24. Cosimi AB, Burton RD, Colvin RB, Goldstein G. 1981. Treatment of cute renal allograft rejection with OKT3 monoclonal antibody. Transplantation. 32:535–539.PubMedGoogle Scholar
  25. Cunningham D, Humblet Y, ,Siena S, Khayat D, et al. 2004. Centuximab monotherapy and centuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. NEJM. 351: 337–345.PubMedGoogle Scholar
  26. Davies AJ, Rohatiner AZ, Howell S, Britton KE, et al. 2004. Tositumomab and Iodine I 131 tositumomab for recurrent indolent and transformed B cell non-Hodgkin’s lymphoma. J Clin Oncol. 22:1469–1479.PubMedGoogle Scholar
  27. Davis TA, White CA, Grillo-Lopez AJ, Velasquez WS, et al. 1999. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: Results of a phase II trial of Rituximab. J Clin Onc. 17:1851–1857.Google Scholar
  28. Dedrick RL, Walicke P, Garovoy M. 2002. Anti-adhesion antibodies efalizumab, a humanized anti-CD11a monoclonal antibody. Transplant Immunol. 9:181–186.Google Scholar
  29. Edwards J, Szczepanski L, Szechinski J, Filipowicz-Sosnowaska A, et al. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. NEJM. 350:2572–2581.PubMedGoogle Scholar
  30. Ettenger RB, Marik J, Rosenthal JT, Fine RN, et al. 1988. OKT3 for rejection reversal in pediatric renal transplantation. Clin Transplant. 2:180–184.Google Scholar
  31. Foote J, Winter G. 1992. Antibody framework residues affecting the conformation of the hypervariable loops. J Mol biol. 224:487–499.PubMedGoogle Scholar
  32. Francis RJ, Sharma SK, Springer C, Green AJ, et al. 2002. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer. 87:600–607.PubMedGoogle Scholar
  33. Gaston RS, Deierhoi MH, Patterson T, Prasthofer E, et al. 1991. OKT3 first-dose reaction: Association with T cell subsets and cytokine release. Kid Internat. 39:141–148.Google Scholar
  34. Goldberg RM. 2006. Therapy for metastatic colorectal cancer. The Oncologist. 11:981–987.PubMedGoogle Scholar
  35. Goldman M, Abramowicz D, DePauw L, Alelgre M, et al. 1989. OKT3-induced cytokine released attenuation by high-dose methylprednisolone. Lancet. 2:802–803.PubMedGoogle Scholar
  36. Goldstein G, Fuccello AJ, Norman DJ, Sheild CF, et al. 1986. OKT3 monoclonal antibody plasma levels during therapy and the subsequent development of host antibodies to OKT3. Transplantation. 42:507–511.PubMedGoogle Scholar
  37. Goncalves LF, Ribeiro AR, Berdichevski R, Joelsons G. 2007. Basiliximab improves graft survival in renal transplant recipients with delayed graft function. Transplant Proc. 39:437–438.Google Scholar
  38. Graves JE, Nunley K, Heffernan MP. 2007. Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab and alefacept. J Am Acad Dermatol. 56:e55–e79.PubMedGoogle Scholar
  39. Griggen JG. 2007. How I treat indolent lymphoma. Blood. 109:4617–4626.Google Scholar
  40. Hale G, Dyer MJS, Clark MR, Phillips JM, et al. 1988. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1 H. Lancet. 2:1394–1399.PubMedGoogle Scholar
  41. Hericourt J, Richet CH. 1895. de la serotherapie dans la traitement du cancer, Physologie Pathologique. 120:567–569.Google Scholar
  42. Hershberger RE, Randall SC, Eisen HJ, Bergh C-H, et al. 2005. Daclizumab to prevent rejection after cardiac transplantation. NEJM. 352:2705–2713.PubMedGoogle Scholar
  43. Himmelweit F. 1960. The Collected Papers of Paul Erlich, Vol. 3,59, Pergmon, London.Google Scholar
  44. Hoogenboom HR. 2005. Selecting and screening recombinant antibody libraries. Nat Biotech. 23:1117–1125.Google Scholar
  45. Hooks MA, Wade CS, Millikan WJ. 1991. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy. 11:26–37.PubMedGoogle Scholar
  46. Hortobagyi GN. 2005. Trastuzumab in the treatment of breast cancer. NEJM. 353:1734–1736.PubMedGoogle Scholar
  47. Hosenpud JD. 2005. Immunosuppression in cardiac transplantation. NEJM. 352:2749–2750.PubMedGoogle Scholar
  48. Hudis CA. 2007. Trastuzumab-mechanism of action and use in clinical practice. NEJM. 357:39–51.PubMedGoogle Scholar
  49. Hudson PJ, Souriau C. 1992. Engineered antibodies. Nat Med. 9:129–134.Google Scholar
  50. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, et al. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM. 350:2335–2342.PubMedGoogle Scholar
  51. Janeway C, Travers P, Walport M, Schlomchik M. 2001. Immunobiology, Fifth Edition, Garland Science, New York and London.Google Scholar
  52. Jazirehi AR, Bonavida B. 2005. Cellular and molecular signal transduction pathways modulated by rituximab (Rituxan, anti-CD20 mab) in non-Hodgkin’s lymphoma: Implications in characterization of therapeutic intervention. Oncogene. 24:2121–2143.PubMedGoogle Scholar
  53. Jensen M, Klehr M, Vogel A, Schmitz S, et al. 2007. One step generation of fully chimeric antibodies using C gamma 1 and C kappa mutant mice. J Immunother. 30:338–349.PubMedGoogle Scholar
  54. Jones PT, Dear PH, Foote J, Neuberger MS, et al. 1986. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 321:522–525.PubMedGoogle Scholar
  55. Kaminski MS, Tuck M, Estes J, Kolstad A, et al. 2005. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. NEJM. 352:441–449.PubMedGoogle Scholar
  56. Kapic E, Becic F, Kusturica J. 2004. Basiliximab, mechanism of action and pharmacological properties. Med Arch. 58:373–376.Google Scholar
  57. King DJ, Adair JR, Angal S, Low DC, et al. 1992. Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab fragment. Biochem J. 281:317–323.PubMedGoogle Scholar
  58. Knight DM, Trinh H, Le J, Siegel S, et al. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol. 30:1443–1453.PubMedGoogle Scholar
  59. Kohler G, Milstein C. 1975. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 256:495–497.PubMedGoogle Scholar
  60. Krauss WC, park JW, Kirpotin DB, Hong K, Benz CC. 2002. Emerging antibody-based HER2 (ErbB-2/neu) therapeutics. Breast Dis. 11:113–124.Google Scholar
  61. Leahy MF, Seymour JF, Hicks RJ, Turner JH. 2006. Multicenter phase II clinical study of Iodine-131-Rituximab radiotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. J Clin Oncol. 24:4418–4425.PubMedGoogle Scholar
  62. Lind P, Lechner P, Hausmann B. 1991. Development of human anti-mouse antibodies (HAMA) after single and repeated diagnostic application of intact murine monoclonal antibodies. Antibody Immunoconjug Radiopharm. 4:811–818.Google Scholar
  63. Littlejohns P. 2006. Trastuzumab for early breast cancer: Evolution or revolution? Lancet Oncol. 7:22–23.PubMedGoogle Scholar
  64. Lo-Coco F, Cimino G, Breccia M, Noguera NI, et al. 2004. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 104: 1995–1999.PubMedGoogle Scholar
  65. Mascelli MA, Zhou H, Sweet R, Getsy J, et al. 2007. Molecular, biologic and pharmacokinetic properties of monoclonal antibodies: Impact of these parameters on early clinical development. J Clin Pharmacol. 47:553–565.PubMedGoogle Scholar
  66. McArthur HL, Chia S. 2007. Cardiotoxicity of trastuzumab in clinical practice. NEJM. 357:94–95.PubMedGoogle Scholar
  67. McCune SL, Gockerman JP, Rizzieri DA. 2001. Monoclonal antibody therapy in the treatment of non-Hodgkin’s lymphoma. JAMA. 286:1149–1152.PubMedGoogle Scholar
  68. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol. 16:2825–2833.PubMedGoogle Scholar
  69. Menter A, Leonardi CL, Sterry W, Bos JD. 2006. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol. 54:S182–S188.PubMedGoogle Scholar
  70. Morris JA, Hanson JE, Steffen BJ, Chu AH, et al. 2005. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant patients. Clin Transplant. 19:340–345.PubMedGoogle Scholar
  71. Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. 1984. Chimeric human antibody molecules: Mouse antigen binding domains with human constant region domains. Proc Natl Acad Sci USA. 81:6851–6855.Google Scholar
  72. Nadler LM, Stashenko P, Hardy R, Kaplan WB, et al. 1980. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma associated antigen. Cancer Res. 40:3147–3154.PubMedGoogle Scholar
  73. O’Dell JR. 2004. Therapeutic strategies for rheumatoid arthritis. NEJM. 350:2591–2602.PubMedGoogle Scholar
  74. Okamoto H. 2006. Effect of rituximab in refractory SLE: Inhibition of Th1. Rheumatology. 45:121–122.PubMedGoogle Scholar
  75. Olsen NJ, Stein CM 2004. New drugs for rheumatoid arthritis. NEJM. 350:2167–2179.PubMedGoogle Scholar
  76. Ortho Multicenter Transplant Study Group. 1985. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. NEJM. 313:337–342.Google Scholar
  77. Pegram M, Hsu S, Lewis G, Pietras R. 1999. Inhibitory effects of combination of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancer. Oncogene. 18:2241–2251.PubMedGoogle Scholar
  78. Pendley C, Schantz A, Wagner C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther. 5:172–179.PubMedGoogle Scholar
  79. Penichet ML, Morrison SL. 2004. Designing and engineering human forms of monoclonal antibodies. Drug Deve Res. 61:121–136.Google Scholar
  80. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, et al. 2005. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEJM. 353:1659–1672.PubMedGoogle Scholar
  81. Piccoli R, Olson KA, Vallee BL, Fett JW. 1998. Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenograft in athymic mice. PNAS USA. 95:4579–4583.PubMedGoogle Scholar
  82. Posner MR, Wirth LJ. 2006. Centuximab and radiotherapy for head and neck cancer. NEJM. 354:634–636.PubMedGoogle Scholar
  83. Present D, Rutgeerts P, Targan S, Hanauer S, et al. 1999. Infliximab for the treatment of fistulas in patients with Crohn’s disease. NEJM. 340:1398–1405.PubMedGoogle Scholar
  84. Presta LG, Lahr SJ, Shields RI, Porter JP, et al. 1993. Humanization of an antibody directed against IgE J Immunol. 151:2623–2632.PubMedGoogle Scholar
  85. Przepiorka D, Kernan NA, Ipppoliti C, Papandopoulas EB, et al. 2000. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for the treatment of acute graft-versus-host disease Blood. 2000:83–89.Google Scholar
  86. Queen C, Schneider WP, Selick HE, Payne PW, et al. 1989. A humanized antibody that binds to the interleukin 2 receptors. PNAS USA. 86:10029–10033.PubMedGoogle Scholar
  87. Rai KR, Freter CD, Mercier RJ, Cooper MR. 2002. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received Fludarabine. J Clin Oncol. 20:3891–3897.PubMedGoogle Scholar
  88. Ramirez CB, Marino IR. 2007. The role of basiliximab induction therapy in organ transplantation. Expert Opin Biol Ther. 7:137–148.PubMedGoogle Scholar
  89. Rawstron AC, Kennedy B, Moreton P, Dickinson AJ, et al. 2004. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood. 103:2027–2031.PubMedGoogle Scholar
  90. Riechmann L, Clark M, Waldmann H, Winter G. 1988. Reshaping human antibodies for therapy. Nature. 332:323–327.PubMedGoogle Scholar
  91. Ritz J, Schlossman SF. 1982. Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 59:1–11.PubMedGoogle Scholar
  92. Roskos LK, Davis CG, Schwag GM. 2004. The clinical pharmacology of therapeutic monoclonal antibodies. Drug Dev Res. 61:108–120.Google Scholar
  93. Rutgeerts P, Sanborn WJ, Feagan BG, Reinisch W, et al. 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. NEJM. 353:2462–2476.PubMedGoogle Scholar
  94. St. Clair EW. 2002. Infliximab treatment for rheumatic disease. Clinical and radiological efficacy. Ann Rehum Dis. 61:ii67–ii69.Google Scholar
  95. Sands B, Anderson F, Bernstein C, Chey W, et al. 2004. Infliximab maintenance therapy for fistulizing Crohn’s disease. NEJM. 350:876–885.PubMedGoogle Scholar
  96. Scheinberg DA, Chapman BA. 1995. In: Birch JR, Lennox ES, Eds. Monoclonal Antibodies: Principles and Applications, Wiley-Liss, New York, pp. 45–105.Google Scholar
  97. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L. 2005. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid refractory graft-versus-host disease. Br J Hemtaol. 130:568–574.Google Scholar
  98. Schmitz U, Versmold A, Kaufmann P, Frank HG. 2000. Phage display: A molecular tool for the generation of antibodies – a review. Placenta. 21:S106–S112.PubMedGoogle Scholar
  99. Schrag D. 2004. The price tag on progress – chemotherapy for colorectal cancer. NEJM. 351:317–319.PubMedGoogle Scholar
  100. Schroeder TJ, Michael AT, First MR, Hariharan S, et al. 1994. Variations in serum OKT3 concentration based upon age, sex, transplanted organ, treatment regimen and anti-OKT3 status. Ther Drug Monit. 16:361–367.PubMedGoogle Scholar
  101. Sfikakis PP. 2002. Behcet’s disease: A new target for anti-tumour necrosis factor treatment. Ann Rheum Dis. 61:ii51–ii56.PubMedGoogle Scholar
  102. Sharkey RM, GHoodenberg DM. 2006. Targeted therapy of cancer: New prospects for antibodies and immuno conjugates. CA Cancer J Clin. 56:226–243.PubMedGoogle Scholar
  103. Shields CJ, Winter DC, Becker JM, Prushik SG, et al. 2006. Infliximab for ulcerative colitis. NEJM. 354:1424–1426.PubMedGoogle Scholar
  104. Shimoni A, Zwas ST, Oksman Y, Hardan I, et al. 2007. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin’s lymphoma. Exp Hematol. 35:534–540.PubMedGoogle Scholar
  105. Smith I, Procter M, Gelber RD, Guillaume S, et al. 2007. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomized controlled trial. Lancet. 369:29–36.PubMedGoogle Scholar
  106. Song H, Du Y, Sgouros G, Prideaux A, et al. 2007. Therapeutic potential of 90Y and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin’s lymphoma with pulmonary involvement. JNM. 48:150–157.PubMedGoogle Scholar
  107. Stern M, Herrmann R. 2005. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol. 54:11–29.PubMedGoogle Scholar
  108. Tan P, Mitchell DA, Buss TN, Holmes MA, et al. 2002. Super humanized antibodies: Reduction of immunogenic potential by complementarity-determining region grafting with human germline sequences: Application to an anti-CD28. J Immunol. 169:1119–1125.PubMedGoogle Scholar
  109. Topol EJ, Moliterno DJ, Hermann HC, Powers ER, et al. 2001. Comparison of two platelet glycoproteins IIb/IIIa inhibitors, Tirofiban and abciximab, for the prevention of ischemic events with precutaneous coronary revascularization. NEJM. 344:1888–1894.PubMedGoogle Scholar
  110. Valabrega G, Montemurro F, Aglietta M. 2007. Trastuzumab: Mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984.PubMedGoogle Scholar
  111. Verbeek WHM, Mulder CJJ, Zweegman S, Vivas S, et al. 2006. Alemtuzumab for refractory celiac disease. NEJM. 355:1396–1397.PubMedGoogle Scholar
  112. Verhoeyen M, Milstein C, Winter G. 1988. Reshaping human antibodies: Grafting an antilysozyme activity. Science. 239:1534–1536.PubMedGoogle Scholar
  113. Vincenti F, Kirkman R, Light S, Bumgardner G, et al. 1998. Interleuin-2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. NEJM. 338:161–165.PubMedGoogle Scholar
  114. Vivas S, Morales JM, Ramos F, Suarez-Vilela D. 2006. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T-cell lymphoma. NEJM. 354:23–24.Google Scholar
  115. Waldmann T.A. 1991. Monoclonal antibodies in diagnosis and treatment. Science. 252:1657–1662.PubMedGoogle Scholar
  116. Waldmann TA, Levy R, Coller BS. 2000. Emerging therapies: Spectrum of applications of monoclonal antibody therapy. Hematology. 2000:394–408.Google Scholar
  117. Waldmann TA. 2003. Immunotherapy: Past, present and future. Nat Med. 9:269–277.PubMedGoogle Scholar
  118. Waldmann TA. 2007. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases and the prevention of allograft rejection: A 25-year personal odyssey. J Clin Immunol. 27:1–18.PubMedGoogle Scholar
  119. Wellington K, Perry CM. 2005. Efalizumab. Am J clin Dermatol. 6:113–118.PubMedGoogle Scholar
  120. White CA. 2004. Radioimmunotherapy in non-Hodgkin’s lymphoma: Focus on 90Y-ibritumonomab tiuxetan (Zevalin). J Exp Ther Oncol. 4:305–316.PubMedGoogle Scholar
  121. Wiseman GA, Witzig, TE. 2005. Yttrium-90 (90Y) ibritumonomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Cancer Biother Radiopharm. 20:185–188.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Creighton University Medical CenterOmahaUSA

Personalised recommendations